There is research on this stock available only to PRO subscribers.
- AntriaBio's once-weekly insulin injection is in early-stage development, but as the examples used have shown, potentially disruptive drugs candidates have warranted rich valuations even at early stages.
- The AB101 weekly insulin injection is taking a novel approach to basal insulin therapy, which has proven effective in animal models.
- Animal data in insulin products has historically shown a high predictability (85%+) of data later seen in humans. This act as votes of confidence for upcoming clinical development.
- Long-acting insulin is currently dominated by Sanofi's Lantus. Thanks to once daily dosing, Lantus sales totaled nearly $8 billion in 2013.
- AntriaBio is taking a unique approach to developing the world's first once weekly insulin therapy.
- Moving from once daily to once weekly dosing has the potential to capture 30-40% of the $10 billion long-acting insulin market.
- We believe AntriaBio shares are attractive today based on the potential for AB101.
- Sustained release drug delivery systems are growing in popularity as patients of various diseases seek to minimize dosage frequency and save on costs especially where needles are involved.
- Diabetes is one of the most diagnosed diseases in the world, with approximately 5.1M deaths associated annually.
- One of the biggest challenges in managing diabetes is compliance on dosing. Some patients find it difficult to adhere to the daily injections.
- Sustained release drug delivery is becoming the answer to the compliance challenge. One sustained release for diabetes is already available in Bydureon, an insulin regulator, but not for insulin itself.
- AntriaBio is developing a basal insulin delivery product called AB101, which aims to cut the frequency of dosing from a daily injection to a weekly injection.